ADVICE SUMMARY

APPLICATION FOR REGISTRATION OF A CHEMICAL PRODUCT

Product name: CUE-MARE A 7 TO 10 DAY INTRAVAGINAL PROGESTERONE TREATMENT FOR MARES
Applicant: BIONICHE ANIMAL HEALTH (A/ASIA) PTY. LTD.
Product number: 62504
Application number: 43237

Purpose of Application and Description of Use: Registration of a 1.72 g/device Progesterone (P4) intravaginal insert product for inducing cyclical ovarian activity in spring transitional mares.

Active Constituent: Progesterone

Regulatory Decision:
To grant the application subject to the following conditions:

Standard Conditions of Registration/Approval

ADVICE

APVMA Residues Program

APVMA Veterinary Residue Team (VRT) assessed the residue aspect of this application. Progesterone or its synthetic analogues (progestins) are administered to animals in order to synchronise oestrus and facilitate natural or artificial insemination. The proposed use of progesterone for the induction of oestrus in mares meets the requirements for an entry into Table 5 of the *MRL Standard*, as progesterone “residues” are identical to, or indistinguishable from, natural food components. VRT advises that the use of the product as per amended label satisfies section 14 (3) (e) (iv) of the Agvet Codes.

Efficacy and Safety:

An external reviewer assessed the Efficacy and Safety aspect of the application.

Cue-Mare A 7 to 10 Day Intravaginal Progesterone Treatment for Mares is a flexible device with Y-shaped arms, attached to which are silicone pods containing progesterone. Progesterone is released from pods over time and absorbed from the vagina into bloodstream to induce the physiological effects.

A trial was conducted to study the appropriate progesterone release profile of Cue Mare in ovariectomised and winter anoestrous mares. The plasma progesterone profiles over 11 days indicated that the devices produced progesterone levels within normal treatment range for an efficacious treatment.

An efficacy trial was conducted on a thoroughbred farm. Cue-Mare product was inserted into the treatment group and removed on day 7 or day 10. When a follicle of greater than 35mm diameter was detected, human chorionic gonadotrophin (hCG) was injected and mares were served using a single stallion 24-36 hours later. The results indicated that the mean day to first service and days to conception were significantly shorter in the treatment group compared to the control group (P<0.05).

Two safety studies showed varying levels of inflammatory response to the Cue-Mare intra vaginal device in all mares. The inflammation resolved within 2 days of device removal in most mares. The devices did not adversely affect endometrial biopsy scores and all mares appeared to tolerate devices to an accepted level with respect to animal welfare and safety considerations.

The external reviewer has advised that when used according to the label instructions, the product will be effective in inducing cyclical ovarian activity in spring transitional mares and not likely to have unintended harmful effect on the target animals.
<table>
<thead>
<tr>
<th>Data No</th>
<th>Data Source*</th>
<th>Author(s)</th>
<th>Title</th>
<th>Date</th>
<th>Data Type</th>
<th>Data Sub-type</th>
<th>Authorising Party</th>
<th>Inherited Application No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>22761</td>
<td>S</td>
<td>M.A. Driancourt, E. Palmer</td>
<td>Seasonal and individual effects on ovarian and endocrine responses of mares to a synchronization treatment with progestagen-impregnated vaginal sponges</td>
<td>1982</td>
<td>Efficacy and Safety</td>
<td>Efficacy</td>
<td>Public</td>
<td></td>
</tr>
<tr>
<td>22758</td>
<td>S</td>
<td>J.B. Grimmett, D.W. Hanlon, G.F. Duirs, W. Jochle</td>
<td>A new intravaginal progesterone-releasing device (Cue-Mare) for controlling the estrous cycle in mares</td>
<td>2002</td>
<td>Efficacy and Safety</td>
<td>Efficacy</td>
<td>Public</td>
<td></td>
</tr>
<tr>
<td>55005</td>
<td>S</td>
<td>D Hanlon</td>
<td>Treatment of Transitional Thoroughbred mares with an intravaginal progesterone releasing device (Cue-Mare)</td>
<td>January 2005</td>
<td>Efficacy and Safety</td>
<td>Efficacy</td>
<td>Applicant</td>
<td></td>
</tr>
<tr>
<td>22756</td>
<td>S</td>
<td>P Plewman</td>
<td>Efficacy Data Package (New Zealand)</td>
<td>September 2005</td>
<td>Efficacy and Safety</td>
<td>Efficacy</td>
<td>Applicant</td>
<td></td>
</tr>
</tbody>
</table>

* S = Data submitted with the application